Listen to the interview below.
Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health, announced today that its Director of Research and Development, Dr. Robert Hesslink, discussed 1-TDC and periodontal disease on Bloomberg Radio.
The company also recently announced the publication of an article on its Boston University study in the July issue of the Journal of Periodontology.
In the recent study, 1-TDC was applied to the gum line using the rabbit periodontitis model developed by Boston University investigators. The study results showed that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group.
Comments on this entry are closed.